Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak
Abstract
The recent Ebola virus outbreak in West Africa illustrates the need not only for a vaccine but for potential therapies, too. One promising therapy is monoclonal antibodies that target Ebola's membrane-anchored glycoprotein (GP). Bornholdt et al. isolated and characterized 349 antibodies from a survivor of the 2014 outbreak. A large fraction showed some neutralizing activity and several were quite potent. Structural analysis revealed an important site of vulnerability on the membrane stalk region of GP. Antibodies targeting this area were therapeutically effective in Ebola virus–infected mice.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 04, 2016
- Source ID
- 10.1126/science.aad5788
Entities
People
- Andrew B Ward
- Arthur J Goff
- Ashley E Piper
- Charles D. Murin
- Colby A. Souders
- Dennis R. Burton
- Devin Sok
- Eric Krauland
- Erica Ollmann Saphire
- Hannah L. Turner
- Heidi L. Smith
- Joshua D. Shamblin
- Karl D. Wittrup
- Kathleen B. J. Pommert
- Keith A. Reimann
- Laura M Walker
- Lisa A. Cavacini
- Mark Klempner
- Marnie L. Fusco
- Pamela J Glass
- Suzanne E. Wollen
- Thomas R. Sprague
- Tillman U. Gerngross
- Wen Li
- Zachary A. Bornholdt
Organizations
- Defense Advanced Research Projects Agency
- Massachusetts Institute of Technology
- National Institutes of Health
- Scripps Research
- United States Army Medical Research Institute of Infectious Diseases